1 – 4 of 4
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
HERA : a new era for health emergency preparedness in Europe?
(
- Contribution to journal › Letter
- 2019
-
Mark
Where is the 'global' in the European Union's Health Research and Innovation Agenda?
(
- Contribution to journal › Article
- 2016
-
Mark
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: Raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART
(
- Contribution to journal › Article
- 2014
-
Mark
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1 : 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial
(
- Contribution to journal › Article